MedTrace Logo

Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension

NCT00999752 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-05-05

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the effects of Nebivolol and Hydrochlorothiazide on blood pressure in African Americans with high blood pressure.

Conditions

Interventions

DRUG

Nebivolol

5mg/day with increase to 10 mg/day to reach blood pressure \<140/90

DRUG

Hydrochlorothiazide

Hydrochlorothiazide 25 mg/day

Sponsors & Collaborators

  • InVasc Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Bobby V Khan, MD PhD · InVasc Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-02-28
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00999752 on ClinicalTrials.gov